Bridging Research and Markets

With increased competition, a shifting regulatory landscape and growing demands from patients and health care providers, life sciences companies face significant challenges and must find ways to differentiate themselves and remain competitive.
We understand the importance of pharmaceuticals and new technologies in delivering value to the health sector and socio-economic landscape, and we help organisations demonstrate this through our methodological approach and use of data and evidence.

Reimagining the Value Chain

We work with experts close to the solution to understand implementation, build robust evidence base, develop and quantify impact pathways and establish a clear product narrative.

Winning hearts and minds – changing behaviour – is as important as a powerful message about the value you can bring. Addressing this needs a constant focus on demonstrating the many dimensions of a technology’s value and understanding, in a very practical way, what needs to change for it to become part of routine treatment.

Our work in this sector

01

Applied Health Economics

  • Evidence-Driven Impact: We empower decision makers with robust analysis and modelling to support teams, regulators and governments to make better, evidence-based decisions.
  • Socio-Economic Strategy: Expect evidence-based socio-economic cost analyses to navigate policy changes and med reclassifications with confidence.
  • Synergistic Business Planning: We craft comprehensive business cases aligning benefits across multiple projects and technologies.
  • Competitive Clarity: We help you strategise market access and product positioning to distinguish your offerings amongst competitors effectively.

02

From Pilots to Market

  • In-Depth Discovery: We conduct thorough reviews of the existing evidence and collect quantitative and qualitative data, including patient and staff interviews, for a complete picture.
  • Impact Pathway Analysis: Uncover modelling of the cost and benefit associated with different impact pathways.
  • Industry Expertise: We are familiar with the barriers new technologies face and are experts in understanding and reporting what needs to change for your technology to become part of routine treatment.
  • End-to-end Service: We can support all stages from the development of your product, coding quality control, and expansion/further roll-out analysis.

03

Pathway Optimisation for Your Product

  • Usage Variation Insights: Detailed analysis of variation in the use of your product/technology to enhance market understanding.
  • Integrated Operations: Combine local clinical and operational expertise to consolidate a single version of the truth making it easier for local systems to adapt and adopt your product.
  • User centred: Outputs tailored to your stakeholders.
  • Medication Reviews: Holistic structured medication reviews including analytical risk assessments.

04

Promote Changes in Prescribing Decisions

  • Scenario Simulations: Simulation based scenario modelling for value optimisation and product comparisons.
  • Pharmaceutical Economic Expertise: Expert economic advice on novel pharmaceutical product frameworks and clinician prescription switching behaviour that have saved the NHS millions.
  • Incentive Innovation: We design novel contracts to realign incentives, fostering mutually beneficial relationships between providers and clients
  • Risk Mitigation: We employ analytics to identify and mitigate risks of marginalising products, ensuring market relevance and sustainability.
  • Patient Cohort Precision: Patient cohorts segmentation using registry and clinical data to tailor treatment strategies and improve care.

Read more about our related work and articles:

See All

Transforming patient experience into valuable insights

Edge Health partnered with a charity-run social network for people with long-term conditions to analyse complex textual data from over 40,000 users, revealing valuable insights into user preferences, treatment discussions, and real-world events, which can help pharmaceutical companies better understand patient needs and optimize product development.

Quantifying the socio-economic impact of changing access to an over-the-counter medicine

Helping the NHS to save £294m through increasing use of the best value biological medicine

Edge Health helped NHS England model pricing and savings scenarios for Adalimumab biosimilars, supporting a new supply framework that led to over £290 million in savings for the NHS, significantly exceeding initial expectations.

A health economic evaluation of Minder

Edge Health conducted a health economic evaluation of Minder, a remote care platform for dementia patients, demonstrating its potential value and return on investment for local populations and health systems across England.

Procurement Cost Saving Analysis

Case study: Evaluating the benefits of integrating chemotherapy patient management apps

Quantifying the private market: an opportunity for NHS trusts

The Value of Clinical Homecare to the NHS, Patients and Society